MSH2 and neoplasm: The heterogeneity in tumour manifestation is also seen in CMMRD cases where MLH1/MSH2 mutations predominantly give rise to, but are not limited to, highly aggressive haematological malignancies, while MSH6 and PMS2 mutations mostly give rise to brain tumours before the age of 10 years.